FOXP1

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Animals1
In silico1

Effects

mTOR signalling

downin human cells1

1 study

FOXP1 inhibits mTOR signalling in human cells.
“FOXP1 activates the target gene SESN3 and inhibits the mTORC1 signaling pathway through phase separation”
Cells
Super-enhancer-driven core transcription factor FOXP1 delays endothelial cell senescence via phase separation-mediated SESN3 activation
Theranostics8 Dec 2025

Associations

Atherosclerosis

downin human cells1

1 study

FOXP1 lowers the risk of atherosclerosis in human cells.
“FOXP1 is identified as a core transcription factor, driven by super-enhancers, which delays endothelial cell senescence and inhibits atherosclerosis.”
Cells
Super-enhancer-driven core transcription factor FOXP1 delays endothelial cell senescence via phase separation-mediated SESN3 activation
Theranostics8 Dec 2025